InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,438.90
(
0.55%
)
Post# of 252301
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 151846

Wednesday, 01/27/2021 11:52:04 AM

Wednesday, January 27, 2021 11:52:04 AM

Post# of 252301
In blow to PFE, Xeljanz LT-safety_study_misses_non-inferiority_endpoints_compared_to_Humira/Enbrel:

https://finance.yahoo.com/news/pfizer-shares-co-primary-endpoint-114500861.html

The study in question was a post-marketing requirement from the FDA’s approval of Xeljanz in 2012. Whether Xeljanz’s label will be updated as a result of the study is unclear at this point.

Xeljanz has annualized worldwide sales of ~$2.5B.

p.s. “Shares” is evidently the new “updates” for biotech PRs bearing bad news.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up